Brenmiller Energy (BNRG) 6-K 29 Aug 24 Report of Foreign Private Issuer Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2024
Document Information Line Items
Entity Registrant Name	BRENMILLER ENERGY LTD.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001901215
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity File Number	001-41402

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 6,966	$ 3,183
Restricted deposits	33	34
Trade receivables, net of allowance for credit losses of $669 and $380 as of June 30, 2024 and December 31, 2023		278
Prepaid expenses and other receivables	558	467
Inventory	625	607
TOTAL CURRENT ASSETS	8,182	4,569
NON-CURRENT ASSETS:
Restricted deposits	81	85
Operating lease right-of-use assets, net	850	1,144
Property, plant and equipment	4,811	4,563
Other asset		233
TOTAL NON-CURRENT ASSETS	5,742	6,025
TOTAL ASSETS	13,924	10,594
CURRENT LIABILITIES:
Trade payables	172	321
Deferred revenue	387	387
Other payables	1,653	1,401
Current maturities of operating lease liabilities	544	611
TOTAL CURRENT LIABILITIES	2,756	2,720
NON-CURRENT LIABILITIES:
European Investment Bank (“EIB”) Loan	4,345	4,461
Warrants’ liability	11
Operating lease liabilities	276	533
TOTAL NON-CURRENT LIABILITIES	4,632	4,994
COMMITMENTS (Note 6c)
TOTAL LIABILITIES	7,388	7,714
SHAREHOLDERS’ EQUITY:
Ordinary Shares, no par value - Authorized 15,000,000 ; Issued and outstanding 5,958,757 and 2,151,745 as of June 30, 2024 and December 31, 2023, respectively	124	124
Additional paid in capital	105,474	100,237
Foreign currency cumulative translation reserve	(2,053)	(2,053)
Accumulated deficit	(97,009)	(95,428)
TOTAL SHAREHOLDERS’ EQUITY	6,536	2,880
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 13,924	$ 10,594

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Net of allowance for credit losses (in Dollars)	$ 669	$ 380
Ordinary shares, par value (in Dollars per share)
Ordinary shares, shares authorized	15,000,000	15,000,000
Ordinary shares, shares issued	5,958,757	2,151,745
Ordinary shares, shares outstanding	5,958,757	2,151,745

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
REVENUES
Engineering services		$ 580
COSTS AND EXPENSES:
COST OF REVENUES	(408)	(1,193)
RESEARCH AND DEVELOPMENT, NET	(1,808)	(1,711)
SELLING AND MARKETING	(616)	(687)
GENERAL AND ADMINISTRATIVE	(2,313)	(2,409)
OTHER INCOME (EXPENSES), NET	(230)	2
OPERATING LOSS	(5,375)	(5,418)
INTEREST EXPENSES	(85)	(69)
OTHER FINANCIAL INCOME, NET	3,879	159
FINANCIAL INCOME (EXPENSES), NET	3,794	90
NET LOSS	$ (1,581)	$ (5,328)
NET LOSS PER ORDINARY SHARE:
Net loss per ordinary share, basic loss (in Dollars per share)	$ (0.45)	$ (3.02)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (in Shares)	3,510,328	1,765,142
NET LOSS, as above	$ (1,581)	$ (5,328)
OTHER COMPREHENSIVE LOSS - EXCHANGE DIFFERENCES ON TRANSLATION TO PRESENTATION CURRENECY (Note 2B)		(423)
COMPREHENSIVE LOSS	(1,581)	(5,751)
Engineering Services
REVENUES
Engineering services		$ 580

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net loss per ordinary share, diluted loss	$ (0.45)	$ (3.02)
Weighted average number of shares outstanding, diluted loss per share	3,510,328	1,765,142

Condensed Consolidated Statemen

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Thousands	Ordinary shares	Additional paid in capital	Foreign currency cumulative translation reserve		Accumulated deficit	Total
Balance at Dec. 31, 2022	$ 88	$ 91,902	$ (1,577)		$ (85,780)	$ 4,633
Balance (in Shares) at Dec. 31, 2022	1,522,398
Comprehensive loss for the period			(423)		(5,328)	(5,751)
Issuance of shares and prefunded warrants, net of issuance costs	$ 28	6,238				6,266
Issuance of shares and prefunded warrants, net of issuance costs (in Shares)	497,426
Share-based compensation	$ 3	1,406				1,409
Share-based compensation (in Shares)	53,523
Balance at Jun. 30, 2023	$ 119	99,546	(2,000)		(91,108)	6,557
Balance (in Shares) at Jun. 30, 2023	2,073,347
Balance at Dec. 31, 2023	$ 124	100,237	(2,053)		(95,428)	$ 2,880
Balance (in Shares) at Dec. 31, 2023	2,151,745					2,151,745
Comprehensive loss for the period					(1,581)	$ (1,581)
Issuance of shares and prefunded warrants, net of issuance costs		5,268				5,268
Issuance of shares and prefunded warrants, net of issuance costs (in Shares)	3,038,421
Exercise of prefunded warrants				[1]			[1]
Exercise of prefunded warrants (in Shares)	648,890
Warrants reclassified to equity (Notes 2B and 5A)		700				700
Warrants classified to liabilities (Note 2B)		(1,649)				(1,649)
Exercise of options		3				3
Exercise of options (in Shares)	1,805
Share-based compensation		915				915
Share-based compensation (in Shares)	117,896
Balance at Jun. 30, 2024	$ 124	$ 105,474	$ (2,053)		$ (97,009)	$ 6,536
Balance (in Shares) at Jun. 30, 2024	5,958,757					5,958,757
[1]Less than $1,000.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 383	$ 49

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS - OPERATING ACTIVITIES:
Loss for the period	$ (1,581)	$ (5,328)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	56	65
Non-cash interest and exchange rate differences, net	(25)	(45)
Fair value adjustment of warrants’ liability	(4,114)
Warrants issuance costs	473
Share-based compensation	915	1,409
Other	233
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and receivables	187	(353)
Decrease (increase) in inventory	(18)	301
Increase (decrease) in trade payables	(149)	331
Increase in other payables and deferred revenue	159	40
Net cash used in operating activities	(3,864)	(3,580)
CASH FLOWS - INVESTING ACTIVITIES:
Purchase of equipment	(26)	(7)
Installation of a production facility	(225)	(2,090)
Restricted deposit withdrawn	4	3
Other		2
Net cash used in investing activities	(247)	(2,092)
CASH FLOWS - FINANCING ACTIVITIES:
Proceeds from issuance of shares and prefunded warrants	5,651	6,087
Proceeds from issuance of warrants’ liability	3,176
Fund raising and issuance costs	(856)	(49)
Exercise of options and warrants	3
Net cash provided by financing activities	7,974	6,038
NET INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED DEPOSITS	3,863	366
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS AND RESTRICTED DEPOSITTS	(81)	(134)
CASH AND CASH EQUIVALENTS AND RESTRICTED DEPOSITS - BEGINNING OF PERIOD	3,217	6,542
CASH AND CASH EQUIVALENTS AND RESTRICTED DEPOSITS - END OF PERIOD	6,999	6,774
Investing and financing activities not involving cash flows
Recognition of operating lease liability and right-of-use asset		144
Borrowing costs capitalized	53	72
Reclassification of warrants from liabilities to equity	700
Conversion of unpaid salary to Ordinary Shares and warrants		228
Reclassification of warrants from equity to liabilities	1,649
C. Reconciliation of cash and cash equivalents, and restricted DEPOSITS reported in the statement of financial position
Cash and cash equivalents	6,966	6,740
Restricted bank deposits	33	34
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 6,999	$ 6,774

General

General	6 Months Ended
	Jun. 30, 2024
General [Abstract]
GENERAL	NOTE 1 - GENERAL: A. General description of the Company and its operations Brenmiller Energy Ltd. (the “Company”) was incorporated and commenced its business operations in Israel in 2012. The Company’s registered offices are in Rosh Ha’Ayin in Israel. On May 25, 2022, the Company’s ordinary shares (the “Ordinary Shares”) were listed and began trading on the Nasdaq Stock Market LLC (“Nasdaq”). On September 11, 2023, the Company’s voluntary delisting of its securities from the Tel Aviv Stock Exchange (“TASE”) took effect (the last trading day was September 7, 2023). The Company is a technology company that develops, produces, markets and sells thermal energy storage (“TES”) systems based on our proprietary and patented bGen™ technology. The use of the Company’s technology allows electrification and decarbonization of the industrial industry sector resulting in better integration with renewable energy sources and further reduction of carbon emissions. Through 2022, the Company’s main activity was focused on the development of its technology and its application into products and commercial solutions. As of June 30, 2024, the Company has three wholly owned subsidiaries (in Israel, the Netherlands and the United States), that are currently inactive, or are in the early stages of operations (“the Group”). B. The impact of the regional war involving Israel On October 7, 2023, Hamas terrorists invaded southern Israel and launched thousands of rockets in a widespread terrorist attack on Israel. On the same day, the Israeli government declared that the country was at war and the Israeli military began to call-up reservists for active duty, including a few of our employees. Our operations could be disrupted by these and future reserve duty call-ups. While none of our facilities or infrastructure have been damaged since the war broke out on October 7, 2023, the import and export of goods may experience disruptions in and out of Israel as a result of such military conflict and terrorist attacks on the sea routes in the Red Sea region. A prolonged war could result in further military reserve duty call-ups in the future as well as irregularities to our supply chain and the movement of components and raw material into Israel and our finished products exported from Israel. The Company operations, including its production facility, are located in Israel. The war has slowed down the Company’s ability to fully operate the new production facility due to delays in delivery of machinery and shortage in man-power caused by military reserve call-ups, in addition, the Company is required to find alternative sources of materials and supplies and to cope with increasing costs. A negative sentiment may also affect international markets that may, in turn, affect the Company commercially and with regard to its ability to raise funds . or expansion to more areas of this war, , C. Liquidity The Company has not yet generated significant revenues from its operations and has an accumulated deficit as of June 30, 2024, as well as a history of net losses and negative operating cash flows. In 2023, the Company commenced the commercialization of its products and services and is currently in the final stages of assembling its new production line that will facilitate the shift in operations from the development stage to commercial operations. However, the Company expects to continue incurring losses and negative cash flows from operations until its products reach profitability. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company has concluded that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. These condensed financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include the continued commercialization of the Company’s products and services, raising capital through a private and public offerings (including and using of ATM ) and the withdrawal of the second tranche of financing from EIB for the purpose of expanding the production facility capacity and through government grants under approved research and development plans and approved projects. In addition, management is planning to find additional cash sources through additional equity and debt financing (see also Note 8). There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce, delay, or adjust its operating expenses, including commercialization of existing products or be unable to expand its operations, as desired.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: A. Basis of presentation: The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with Securities and Exchange Commission (“SEC”)’s Regulation S-X. As permitted under those rules, certain footnotes and other financial information that are normally required by generally accepted accounting principles in the United States ( “U.S. GAAP”) can be condensed or omitted. These financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of its financial position as of and for the periods presented. These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023. The results of operations for the six months ended June 30, 2024, are not necessarily indicative of results that could be expected for the 2024 fiscal year or any other interim period or for any other future year. All intercompany transactions and balances have been eliminated in consolidation. B. Change in functional currency Effective January 1, 2024 the Company changed its functional currency to the U.S. dollar from the New Israel Shekel (“NIS”). Prior to this change, the Group’s presentation currency used in its consolidated financial statements was the U.S. Dollar ($), while translation differences from NIS were carried to “Other Comprehensive Income or Loss”. This change was based on the assessment by the Company’s management, that the dollar has become the primary economic environment in which the Company operates, after considering several factors and changes in circumstances in 2023 including inter alia: the commercialization of the Company’s products, changes in the composition of its cost of sales, available funds are mainly denominated in U.S. dollars, and the fact that the Company’s principal source of financing, following the delisting of its shares from trading in TASE, is derived from the U.S. capital markets (Note 5A), and all of the Company’s budgeting is conducted mainly in U.S. dollars. The change in functional currency was accounted for prospectively. The change in functional currency to the U.S. dollar resulted inter-alia in a reclassification of the Company’s certain equity-classified warrants (whose fair value as of January 1, 2024 was $1,649 thousand), to liabilities due to their NIS-denominated exercise price. See also Note 5A, as to changes in the currency of exercise price made during the reporting period. C. Use of estimates in the preparation of financial statements: The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Estimates are primarily used for, but not limited to, valuation of share-based compensation, useful lives of property, plant and equipment and royalty liabilities. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates, and such differences may have a material impact on the Company’s financial position or results of operations. D. Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of trade and other receivables, and cash, cash equivalents and restricted deposits held at financial institutions . The Company places its cash and cash equivalents, bank deposits and restricted deposits in high credit quality financial institutions. In general, customers are not required to provide collateral or any other security to support accounts receivable but are required to make advances with the advancement of projects . Current expected credit loss expense is $289 thousand and $ NIL . E. New Accounting Pronouncements ASU 2023-09—Income Taxes (Topic 740), effective for the Company for annual periods commencing on or after December 15, 2025, and ASU 2023-07—Segment Reporting (Topic 280), effective annual periods commencing on or after December 15, 2023, and for interim periods, on or after December 15, 2024, will require improvements to Income Tax and Reportable Segment disclosures. These are not expected to have a material effect on the consolidated financial statements as a result of their future adoption.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 3 - Fair value measurements Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs that are used when little or no market data is available. The carrying amount of the cash and cash equivalents, restricted deposits, trade receivable, trade payables, other receivable and EIB loan, approximates their fair value. As of June 30, 2024, except for warrants liability of $11 thousand (Note 5A(1); level 2 in the hierarchy), and December 31, 2023, the company has no financial instruments measured at fair value.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2024
Inventory [Abstract]
INVENTORY	NOTE 4 - INVENTORY: Comprised as follows (U.S. dollars in thousands): June 30, December 31, Work in progress $ 565 $ 546 Raw materials 60 61 $ 625 $ 607

Equity

Equity	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
EQUITY	NOTE 5 - EQUITY: A. Share capital and warrants 1) On January 1, 2024, as a result of the change in the functional currency of the Company (Note 2B.) all outstanding warrants issued under private placements on February 16, 2023 and June 15, 2023 that had exercise price denominated in NIS, could have not been considered anymore as indexed to the Company’s own shares, and therefore were reclassified from equity to liabilities at their fair value of $1,649 thousand (valued, as of that date, using the Black - Scholes pricing model). Subsequently, and after receiving the approval of the warrants holders (except for two individuals) to fix the exercise price of such warrants in US Dollars terms (converted from NIS to US Dollars based on the exchange rate as of May 16, 2024), and after the approval of the Board of Directors of the Company, on May 23, 2024, all consented warrants were reclassified to equity at their present fair value of $219 thousand (valued at modification date under the Black - Scholes pricing model, under the following assumptions: risk free interest rate 4.53%-4.71%, expected term 3.6-4 years, expected price volatility of 100%-103%, fair value of an ordinary share of $1.55 and 0% dividend yield); consequently, the Company recognized $1,419 thousand in financial income for the period, resulting from the change in fair value of the warrants’ liability. The remaining liability of $11 thousand is presented among long-term liabilities. 2) On January 25, 2024, the Company closed a public offering under which it completed the issuance and sale of 240,000 Ordinary Shares, no par value per share of the Company at a price of $4.50 per share, pre-funded warrants at a price of $4.4999, to purchase 648,890 Ordinary Shares (which were all exercised into shares on May 17, 2024) and warrants to purchase 888,890 Ordinary Shares at an exercise price of $5.00 per share. The Warrants were exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants were exercisable immediately at a price of $0.0001 per share and were exercisable until exercised in full. The Ordinary Shares, Warrants and Pre-Funded Warrants were offered and sold pursuant to an effective Registration Statement on Form F-1, as amended. The aggregate gross proceeds from this offering were approximately $4.0 million before deducting placement agent fees of $280 thousand and other fund-raising expenses, of $316 thousand. Following their issuance, the Company determined that some of the features of the warrants, did not meet the “indexed to Company’s own stock” criteria, and are therefore precluded from equity classification. Consequently, the gross proceeds received in the offering were initially allocated to the warrant’s that were classified as a liability, based on their fair value, and the residual was allocated to the shares and the prefunded warrants. Upon issuance, the warrants were valued at $3,176 thousand using the Black-Scholes pricing model, under the following assumptions: fair value of an ordinary share - $4.89, expected option term of 5 years, expected price volatility of 93%, risk-free annual interest rate of 4.51% and dividend yield of 0%. Issuance costs were proportionally allocated to the issued financial instruments based on the proceed amounts allocated to such instruments. Consequently, $473 thousand of issuance costs, that were allocated to the warrants, were carried directly to financial expenses. The features of these warrants were amended under an agreement with the holding investor which became effective on June 6, 2024. Consequently, the Company reclassified these warrants to equity at their fair value of $481 thousand (valued under the Black - Scholes pricing model under the following assumptions: : risk free interest rate 4.3%, expected term 4.6 years, expected price volatility of 100%, fair value of an ordinary share of $1.07 and 0% dividend yield) and recognized financial income from the change in their fair value of $2,695 thousand. 3) On April 10, 2024, the Company filed a registration statement on Form S-8 under the Securities Act of 1933, as amended, to register additional 500,000 Ordinary Shares, in the aggregate, issued or reserved for issuance under the 2013 Option Plan. 4) The following table presents the outstanding warrants, as of June 30, 2024 and their terms: Date of issuance Number of Exercise price Expiration date February 16, 2023 181,575 $16.66 February 1, 2028 February 16, 2023 52,251 (*) NIS 61.3 February 1, 2028 January 24, 2023 14,822 (*) NIS 61.3 January 24, 2025 June 15, 2023 248,778 $12.0 June 12, 2028 January 25, 2024 888,890 $5.0 January 25, 2029 (*) Presented as a warrants' liability in the balance sheet, see note A(1) above. 5) During the first half of 2024, under the agreement with a A.G.P./Alliance Global Partners (the “Sales Agent”), the Company issued 2,798,421 ordinary shares, for a total consideration of approximately $4.8 million; agent commissions and other issuance costs amounted $260 thousand. B. Share-based payment: During the six month period ended June 30 2024, the Company granted 115,635 fully vested RS to service providers, valued $158 thousand and granted bonuses to employees and service providers, in share based payment valued under the Black - Scholes pricing model at $ 535 thousand, which included 222,034 fully vested RS (which were formally issued subsequent to June 30, 2024), and 24,544 fully vested options exercisable at $0.01 per share to 24,544 Shares (to service providers; valued at $53 thousand). An additional bonus valued at $89 thousand is awaiting shareholder meeting approval (required under Israeli Law) and therefor was not yet recognized as an expense for the period. Aforesaid approval was obtained on August 8, 2024. Information on the share option awards outstanding and the related weighted average exercise price as of and for the Six months ended June 30, 2024, are presented in the table below: Relating to options: Number of Exercise price Aggregate Outstanding at beginning of the period 133,976 $0.82 - $247.1 $ 57,959 Granted 27,544 $0.01 - $10.7 $ 53,015 Exercised** (1,805 ) $1.60 $ 7,565 Forfeited (4,272 ) $40.0 - $62.2 - Expired (5,360 ) $38.3 - $48.6 - Outstanding at end of the year 150,083 $0.01 - $247.1 $ 23,525 Exercisable at end of the year 114,535 $0.01 - $247.1 $ 23,525 * Per 1 Ordinary Share of with no par value. Exercise price is quoted in denominated currency (see also Note 2B). ** Average share price for options exercised in 2024 – $ 5.79 . The following table summarizes information about stock-based awards outstanding and exercisable at June 30, 2024: Outstanding Exercisable Exercise price range Number of potential Weighted average remaining Number of Ordinary Weighted average $10.7 - $0.01 39,083 5.9 36,083 6.2 $61.4 - $40.0 55,375 6.4 37,683 6.3 $76.7 19,425 1.0 14,569 1.0 $ 100 6,200 4.0 6,200 4.0 $123.5; $185.3; $247.1 30,000 7.7 20,000 7.7 $0.01 - $247.1 150,083 5.8 114,535 5.7 Share-based compensation expense for the periods ended June 30, 2024 and 2023 was as follows (U.S. dollars in thousands): Six months ended June 30 2024 2023 Cost of revenue 8 6 8 Research and development 292 379 Sales and marketing 124 209 General and administrative 491 753 Total share-based compensation expenses 915 1,409 As of June 30, 2024, there is an unrecognized share-based compensation expense of $152 thousand to be recognized over the average remaining vesting period of 1 years. The calculated fair value of options granted was estimated using the Black-Scholes pricing model with the following assumptions: Six months period ended 2024 2023 Risk-free interest rate 3.92%-4.4% 4.75% Expected option term (in years) 3-5 10.0 Expected price volatility 96%-103% 76% Fair value of an ordinary share $2.17-$6.10 NIS 32.6 Dividend yield 0% 0%

Certain Transactions

Certain Transactions	6 Months Ended
	Jun. 30, 2024
Certain Transactions [Abstract]
Certain transactions	NOTE 6 Certain transactions: A. Joint cooperation agreement with an Israeli Beverage Producer (“Tempo”) The initial stage of planning of the TES facility to be constructed on Tempo’s premises commenced on June 10, 2024, investments to date are immaterial. B. Wolfson Medical Center Under the agreement with the Wolfson Medical Center signed in January 2024 (as described in the 2023 annual consolidated financial statements), the Company is in the process of obtaining the regulatory permission to the construction of the TES system on the hospital grounds. C. Product & Service Distribution Agreement On June 3, 2024, the Company entered into an agreement with a United States domiciled third party, that will act as an exclusive distributor of the Company’s products and services in certain US states in North America (“the Distributor”), for a period of 5 years, subject to the Distributor’s achievement of certain targets, milestones and KPIs for each year within the term. Having achieved these targets and milestones, the agreement will be extended for additional 5 years. In addition to payments for the Company’s products and services, the Company shall be entitled to royalties of 10% from the net price attributed to any customer for sale of products and services (net price - net of payments to the Company on purchase orders and O&M service agreements). The Company may yet establish local bGen TES System manufacturing capabilities in the territory or offer sale prospects and/or customers in the territory various forms of EaaS (Energy as a Service) business model without limitation, which does not preclude the Distributor’s right to receive equipment profit margin.

Supplementry Financial Statemen

Supplementry Financial Statement Information	6 Months Ended
	Jun. 30, 2024
Supplementry Financial Statement Information [Abstract]
SUPPLEMENTRY FINANCIAL STATEMENT INFORMATION	NOTE 7 - SUPPLEMENTRY FINANCIAL STATEMENT INFORMATION A. REVENUES: In the six month period ended June 30, 2023, the Company recognized revenue from engineering services provided to a customer in Europe (100%). Revenue recognized that was included in the contract liability balance (deferred revenue) at the beginning of the reported interim periods ended June 30, 2024 and 2023, amounts to $ NIL thousand B. COST OF REVENUES (U.S. dollars in thousands): Six months ended 2024 2023 Salary and related expenses - 392 Consultants and subcontractors - 112 Royalties - 79 - 583 Operating costs not attributed to projects (mainly salary and related expenses) * 408 610 408 1,193 * Cost and expenses relating to periods in which the plant did not operate in full capacity. C. RESEARCH AND DEVELOPMENT, NET (U.S. dollars in thousands): Six months ended June 30, 2024 2023 Salary and related expenses 1,363 1,332 Consultants and subcontractors 210 188 Expenditure on materials 39 59 Depreciation and other 19 53 Office maintenance 177 173 1,808 1,805 Less - Government Grants - (94 ) 1,808 1,711 D. SELLING AND MARKETING (U.S. dollars in thousands): Six months ended 2024 2023 Salary and related expenses 439 548 Office maintenance 18 18 Project Promotion 21 32 Consultants 51 59 Other 87 30 616 687 E. GENERAL AND ADMINISTRATIVE (U.S. dollars in thousands): Six months ended June 30, 2024 2023 Salary and related expenses 934 1,322 Office maintenance 91 88 Consultants and insurance 945 903 Allowance for credit losses 289 - Depreciation and other 54 96 2,313 2,409 F. OTHER INCOME (EXPENSES), NET Due to the continued efforts and difficulties involved in selling the remaining asset from the closure of the Rotem 1 project, the Company’s management decided to write off its remaining value of $229 thousand, which is included in the other operating expenses of the period. G. OTHER FINANCIAL INCOME AND EXPENSES, NET (U.S. dollars in thousands): Financial income: Six months ended 2024 2023 Interest income 76 90 Fair value adjustments of warrants (Note 5A) 4,114 - Warrants issuance costs (473 ) - Exchange rate differences, Net 172 56 Bank fees (10 ) (7 ) Other adjustment of royalty obligation - 20 3,879 159 H. Loss per ordinary share: Basic loss per share is computed by dividing net income or loss, by the weighted-average number of Ordinary Shares outstanding during the period, including prefunded warrants with token exercise price (“penny” warrants). Diluted loss per share is based on the weighted average number of Ordinary Shares used for basic computation, as the inclusion of any potential Ordinary Shares in the reported years would be anti-dilutive. Potentially dilutive Ordinary Shares result from the assumed exercise of options and warrants, using the “treasury stock” method, and the assumed vesting of restricted shares. Basic and diluted loss per share is computed as follows: Six months ended 2024 2023 Numerator ($ in thousands): Net loss for the year, as reported, attributable to shareholders (1,581 ) (5,328 ) Denominator (Ordinary Shares in thousands) Weighted average number of shares outstanding during the year* 2,941,377 1,749,876 Weighted average number of potential shares under prefunded warrants with token exercise price (“penny” warrants) 568,951 15,266 Denominator for basic and diluted loss per share - weighted number of Ordinary Shares 3,510,328 1,765,142 Basic and dilutive loss per Ordinary Share (in dollars) (0.45 ) (3.02 ) * Including the equivalent of the weighted average number of fully vested restricted shares granted during the period of six month ended June 30, 2024 (see Note 5B) of 55,202 shares, that were formally issued subsequent to June 30, 2024). For the reported periods, all outstanding options and warrants have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. These include as of June 30, 2024: Share option and warrants exercisable to 1,500,317 Ordinary Shares that, as of June 30, 2024 that have zero effect under the treasury stock method, and share options that are “in the money” exercisable to 11,539 Ordinary Shares.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 - SUBSEQUENT EVENTS: A. On July 8, 2024, the Company signed an amendment to the credit facility agreement with the European Investment Bank (“EIB”). Following the Amendment, the availability of the second tranche of €3.5 million to the expansion of the Company’s plant, was extended by one year (to March 31, 2025), subject to certain conditions, with a 5.0% fixed annual interest rate. B. On August 4, 2024, the Company entered into a definitive securities purchase agreement with Alpha Capital Anstalt (“Alpha”) for a private placement of 1,000,000 Ordinary Shares at a price of $1.05 per share. The closing of the private placement is subject to certain conditions, including obtaining consent from an existing lender within 90 days of signing the agreement. Under the terms of the agreement, the investor will have a one-time future investment right, from the date hereof until the date that is 12 months after the closing date, to subscribe for an additional 1,000,000 Ordinary Shares (or at the election of the Investor pre-funded warrants to purchase up to 1,000,000 Ordinary Shares in lieu of Ordinary Shares) at a price of $2.50 per ordinary share (or pre-funded warrant), in a private placement. This future investing right will trigger upon the Company’s Ordinary Shares closing on Nasdaq at or above $2.50 per ordinary share (“trigger date”). Any Investor that desires to undertake such future investment shall notify the Company in writing no later than 4:00pm (New York City time) on the fifth (5th) business day following the trigger date. Under the terms of the agreement the parties have also undertaken certain restriction with regard to exercise of rights, so that the investor would not beneficially own in excess of the beneficial ownership limitation of 24.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2024
Significant Accounting Policies [Abstract]
Basis of presentation	A. Basis of presentation: The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with Securities and Exchange Commission (“SEC”)’s Regulation S-X. As permitted under those rules, certain footnotes and other financial information that are normally required by generally accepted accounting principles in the United States ( “U.S. GAAP”) can be condensed or omitted. These financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of its financial position as of and for the periods presented. These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023. The results of operations for the six months ended June 30, 2024, are not necessarily indicative of results that could be expected for the 2024 fiscal year or any other interim period or for any other future year. All intercompany transactions and balances have been eliminated in consolidation.
Change in functional currency	B. Change in functional currency Effective January 1, 2024 the Company changed its functional currency to the U.S. dollar from the New Israel Shekel (“NIS”). Prior to this change, the Group’s presentation currency used in its consolidated financial statements was the U.S. Dollar ($), while translation differences from NIS were carried to “Other Comprehensive Income or Loss”. This change was based on the assessment by the Company’s management, that the dollar has become the primary economic environment in which the Company operates, after considering several factors and changes in circumstances in 2023 including inter alia: the commercialization of the Company’s products, changes in the composition of its cost of sales, available funds are mainly denominated in U.S. dollars, and the fact that the Company’s principal source of financing, following the delisting of its shares from trading in TASE, is derived from the U.S. capital markets (Note 5A), and all of the Company’s budgeting is conducted mainly in U.S. dollars. The change in functional currency was accounted for prospectively. The change in functional currency to the U.S. dollar resulted inter-alia in a reclassification of the Company’s certain equity-classified warrants (whose fair value as of January 1, 2024 was $1,649 thousand), to liabilities due to their NIS-denominated exercise price. See also Note 5A, as to changes in the currency of exercise price made during the reporting period.
Use of estimates in the preparation of financial statements	C. Use of estimates in the preparation of financial statements: The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Estimates are primarily used for, but not limited to, valuation of share-based compensation, useful lives of property, plant and equipment and royalty liabilities. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates, and such differences may have a material impact on the Company’s financial position or results of operations.
Concentration of Credit Risk	D. Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of trade and other receivables, and cash, cash equivalents and restricted deposits held at financial institutions . The Company places its cash and cash equivalents, bank deposits and restricted deposits in high credit quality financial institutions. In general, customers are not required to provide collateral or any other security to support accounts receivable but are required to make advances with the advancement of projects . Current expected credit loss expense is $289 thousand and $ NIL .
New Accounting Pronouncements	E. New Accounting Pronouncements ASU 2023-09—Income Taxes (Topic 740), effective for the Company for annual periods commencing on or after December 15, 2025, and ASU 2023-07—Segment Reporting (Topic 280), effective annual periods commencing on or after December 15, 2023, and for interim periods, on or after December 15, 2024, will require improvements to Income Tax and Reportable Segment disclosures. These are not expected to have a material effect on the consolidated financial statements as a result of their future adoption.

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2024
Inventory [Abstract]
Schedule of Inventory	Comprised as follows (U.S. dollars in thousands): June 30, December 31, Work in progress $ 565 $ 546 Raw materials 60 61 $ 625 $ 607

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Outstanding Warrants	The following table presents the outstanding warrants, as of June 30, 2024 and their terms: Date of issuance Number of Exercise price Expiration date February 16, 2023 181,575 $16.66 February 1, 2028 February 16, 2023 52,251 (*) NIS 61.3 February 1, 2028 January 24, 2023 14,822 (*) NIS 61.3 January 24, 2025 June 15, 2023 248,778 $12.0 June 12, 2028 January 25, 2024 888,890 $5.0 January 25, 2029 (*) Presented as a warrants' liability in the balance sheet, see note A(1) above.
Schedule of Share Option Awards Outstanding and the Related Weighted Average Exercise Price	Information on the share option awards outstanding and the related weighted average exercise price as of and for the Six months ended June 30, 2024, are presented in the table below: Relating to options: Number of Exercise price Aggregate Outstanding at beginning of the period 133,976 $0.82 - $247.1 $ 57,959 Granted 27,544 $0.01 - $10.7 $ 53,015 Exercised** (1,805 ) $1.60 $ 7,565 Forfeited (4,272 ) $40.0 - $62.2 - Expired (5,360 ) $38.3 - $48.6 - Outstanding at end of the year 150,083 $0.01 - $247.1 $ 23,525 Exercisable at end of the year 114,535 $0.01 - $247.1 $ 23,525 * Per 1 Ordinary Share of with no par value. Exercise price is quoted in denominated currency (see also Note 2B). ** Average share price for options exercised in 2024 – $ 5.79 .
Schedule of Stock-Based Awards Outstanding	The following table summarizes information about stock-based awards outstanding and exercisable at June 30, 2024: Outstanding Exercisable Exercise price range Number of potential Weighted average remaining Number of Ordinary Weighted average $10.7 - $0.01 39,083 5.9 36,083 6.2 $61.4 - $40.0 55,375 6.4 37,683 6.3 $76.7 19,425 1.0 14,569 1.0 $ 100 6,200 4.0 6,200 4.0 $123.5; $185.3; $247.1 30,000 7.7 20,000 7.7 $0.01 - $247.1 150,083 5.8 114,535 5.7
Schedule of Share-Based Compensation Expense	Share-based compensation expense for the periods ended June 30, 2024 and 2023 was as follows (U.S. dollars in thousands): Six months ended June 30 2024 2023 Cost of revenue 8 6 8 Research and development 292 379 Sales and marketing 124 209 General and administrative 491 753 Total share-based compensation expenses 915 1,409
Schedule of Fair Value of Option Grants was Estimated Using the Black-Scholes Pricing Model	The calculated fair value of options granted was estimated using the Black-Scholes pricing model with the following assumptions: Six months period ended 2024 2023 Risk-free interest rate 3.92%-4.4% 4.75% Expected option term (in years) 3-5 10.0 Expected price volatility 96%-103% 76% Fair value of an ordinary share $2.17-$6.10 NIS 32.6 Dividend yield 0% 0%

Supplementry Financial Statem_2

Supplementry Financial Statement Information (Tables)	6 Months Ended
	Jun. 30, 2024
Supplementry Financial Statement Information [Abstract]
Schedule of Cost of Expenses (Cost of Revenues, Research and Development, Net, Selling and Marketing, General and Administrative)	Six months ended 2024 2023 Salary and related expenses - 392 Consultants and subcontractors - 112 Royalties - 79 - 583 Operating costs not attributed to projects (mainly salary and related expenses) * 408 610 408 1,193 * Cost and expenses relating to periods in which the plant did not operate in full capacity. RESEARCH AND DEVELOPMENT, NET (U.S. dollars in thousands): Six months ended June 30, 2024 2023 Salary and related expenses 1,363 1,332 Consultants and subcontractors 210 188 Expenditure on materials 39 59 Depreciation and other 19 53 Office maintenance 177 173 1,808 1,805 Less - Government Grants - (94 ) 1,808 1,711 SELLING AND MARKETING (U.S. dollars in thousands): Six months ended 2024 2023 Salary and related expenses 439 548 Office maintenance 18 18 Project Promotion 21 32 Consultants 51 59 Other 87 30 616 687 GENERAL AND ADMINISTRATIVE (U.S. dollars in thousands): Six months ended June 30, 2024 2023 Salary and related expenses 934 1,322 Office maintenance 91 88 Consultants and insurance 945 903 Allowance for credit losses 289 - Depreciation and other 54 96 2,313 2,409
Schedule of Financial Income	Financial income: Six months ended 2024 2023 Interest income 76 90 Fair value adjustments of warrants (Note 5A) 4,114 - Warrants issuance costs (473 ) - Exchange rate differences, Net 172 56 Bank fees (10 ) (7 ) Other adjustment of royalty obligation - 20 3,879 159
Schedule of Basic and Diluted Loss Per Share	Basic and diluted loss per share is computed as follows: Six months ended 2024 2023 Numerator ($ in thousands): Net loss for the year, as reported, attributable to shareholders (1,581 ) (5,328 ) Denominator (Ordinary Shares in thousands) Weighted average number of shares outstanding during the year* 2,941,377 1,749,876 Weighted average number of potential shares under prefunded warrants with token exercise price (“penny” warrants) 568,951 15,266 Denominator for basic and diluted loss per share - weighted number of Ordinary Shares 3,510,328 1,765,142 Basic and dilutive loss per Ordinary Share (in dollars) (0.45 ) (3.02 ) * Including the equivalent of the weighted average number of fully vested restricted shares granted during the period of six month ended June 30, 2024 (see Note 5B) of 55,202 shares, that were formally issued subsequent to June 30, 2024).

Significant Accounting Polici_2

Significant Accounting Policies (Details) - USD ($) $ in Thousands		6 Months Ended
	Jan. 01, 2024	Jun. 30, 2024	Jun. 30, 2023
Significant Accounting Policies [Abstract]
Warrant	$ 1,649
Credit loss expense		$ 289

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value Measurements [Abstract]
Warrants liability	$ 11

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Inventory [Abstract]
Work in progress	$ 565	$ 546
Raw materials	60	61
Inventory, Net	$ 625	$ 607

Equity (Details) - Part-1

Equity (Details) - Part-1 - USD ($)				6 Months Ended
	May 23, 2024	Jan. 25, 2024	Jan. 01, 2024	Jun. 30, 2024	Jun. 30, 2023	Apr. 10, 2024	Dec. 31, 2023
Equity [Line Items]
Reclassified from equity to liabilities			$ 1,649,000
Warrants	$ 1,419,000			$ (4,114,000)
Interest rate				4.30%
Expected terms				4 years 7 months 6 days
Expected price volatility				100%
Ordinary shares (in Shares)	1.55			1.07
Dividend yield	0%			0%
Long term liabilities				$ 11,000
Issuance and sale of ordinary shares (in Shares)		240,000
Price per share (in Dollars per share)		$ 4.5
Pre funded warrants		$ 4.4999
Exercise of prefunded warrants (in Shares)		648,890
Exercise price (in Dollars per share)		$ 5
Warrant, Exercise Price, Decrease (in Dollars per share)		$ 0.0001
Agent fees				280,000
Fund raising expenses				316,000
Proceeds from issuance of warrant liabilities				$ 3,176,000
Issuance of additional ordinary shares (in Shares)				4.89
Warrant exercisable issuance term				4 years 6 months 3 days
Issuance cost				$ 473,000
Changes in fair value				$ 2,695,000
Shares issued (in Shares)				2,798,421
Total consideration				$ 4,800,000
Commission and other issuance cost				260,000
Bonus payment				158,000
Share based payment				$ 535
Vested share options (in Shares)				222,034
Ordinary shares issued (in Shares)				5,958,757			2,151,745
Shares of vested options exercisable (in Shares)				24,544
Additional bonus				$ 89,000
Average price exercised (in Dollars per share)				$ 5.79
Unrecognized share-based compensation expense				$ 152,000
Vesting period				1 year
Warrant [Member]
Equity [Line Items]
Warrants	$ 219
Long term liabilities				$ 11,000
Purchase ordinary shares (in Shares)		888,890
Minimum [Member]
Equity [Line Items]
Interest rate	4.53%
Expected terms	3 years 7 months 6 days
Expected price volatility	100%
Maximum [Member]
Equity [Line Items]
Interest rate	4.71%
Expected price volatility	103%
Share Capital and Warrant [Member]
Equity [Line Items]
Expected terms				5 years
Expected price volatility				93%
Dividend yield				0%
Black and Scholes formula [Member]
Equity [Line Items]
Warrants				$ 481,000
Shares issued (in Shares)				115,635
Share Capital [Member]
Equity [Line Items]
Shares issued (in Shares)						500,000
Board of Directors Chairman [Member]
Equity [Line Items]
Ordinary shares issued (in Shares)				24,544
Exercisable price per share (in Dollars per share)				$ 0.01
Private Placement [Member]
Equity [Line Items]
Aggregate gross proceeds from offering				$ 4,000,000

Equity (Details) - Schedule of

Equity (Details) - Schedule of Outstanding Warrants		Jun. 30, 2024 $ / shares shares	Jun. 30, 2024 ₪ / shares shares	Dec. 31, 2008
February 16, 2023 [Member]
Schedule of Outstanding Warrants [Line Items]
Number of outstanding warrants (in Shares) | shares		181,575	181,575
Exercise price for one Ordinary share		$ 16.66
Expiration date				Feb. 01, 2028
Exercise price for one Ordinary share (in New Shekels per share)		$ 16.66
February Sixteen Twenty Twenty Three One [Member]
Schedule of Outstanding Warrants [Line Items]
Number of outstanding warrants (in Shares) | shares	[1]	52,251	52,251
Exercise price for one Ordinary share | ₪ / shares			₪ 61.3
Expiration date				Feb. 01, 2028
Exercise price for one Ordinary share (in New Shekels per share) | ₪ / shares			₪ 61.3
January 24, 2023 [Member]
Schedule of Outstanding Warrants [Line Items]
Number of outstanding warrants (in Shares) | shares	[1]	14,822	14,822
Exercise price for one Ordinary share | ₪ / shares			₪ 61.3
Expiration date				Jan. 24, 2025
Exercise price for one Ordinary share (in New Shekels per share) | ₪ / shares			₪ 61.3
June 15, 2023 [Member]
Schedule of Outstanding Warrants [Line Items]
Number of outstanding warrants (in Shares) | shares		248,778	248,778
Exercise price for one Ordinary share		$ 12
Expiration date				Jun. 12, 2028
Exercise price for one Ordinary share (in New Shekels per share)		$ 12
January 25, 2024 [Member]
Schedule of Outstanding Warrants [Line Items]
Number of outstanding warrants (in Shares) | shares		888,890	888,890
Exercise price for one Ordinary share		$ 5
Expiration date				Jan. 25, 2029
Exercise price for one Ordinary share (in New Shekels per share)		$ 5
[1]Presented as a warrants' liability in the balance sheet, see note A(1) above.

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of Share Option Awards Outstanding and the Related Weighted Average Exercise Price $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Equity (Details) - Schedule of Share Option Awards Outstanding and the Related Weighted Average Exercise Price [Line Items]
Number of potential Ordinary shares Outstanding at beginning of the year (in Shares) | shares	133,976
Aggregate Intrinsic value Outstanding at beginning of the year (in Dollars) | $	$ 57,959
Number of potential ordinary shares Exercisable at end of the year (in Shares) | shares	114,535
Aggregate Intrinsic value Exercisable at end of the year (in Dollars) | $	$ 23,525
Number of potential ordinary shares Granted (in Shares) | shares	27,544
Exercise price range Granted		[1]
Aggregate Intrinsic value Granted	$ 53,015
Number of potential ordinary shares Exercised (in Shares) | shares	(1,805)	[2]
Exercise price range Exercised	$ 1.6	[2]
Aggregate Intrinsic value Exercised (in Dollars) | $	$ 7,565	[2]
Number of potential ordinary shares Forfeited (in Shares) | shares	(4,272)
Exercise price range Forfeited		[1]
Aggregate Intrinsic value Forfeited
Number of potential ordinary shares Expired (in Shares) | shares	(5,360)
Exercise price range Expired		[1]
Aggregate Intrinsic value Expired
Number of potential ordinary shares Outstanding at end of the year (in Shares) | shares	150,083
Exercise price range Outstanding at end of the year		[1]
Aggregate Intrinsic value Outstanding at end of the year (in Dollars) | $	$ 23,525
Minimum [Member]
Equity (Details) - Schedule of Share Option Awards Outstanding and the Related Weighted Average Exercise Price [Line Items]
Exercise price range Outstanding at beginning of the year	$ 0.82	[1]
Exercise price range Exercisable at end of the year	0.01	[1]
Exercise price range Granted	0.01
Exercise price range Forfeited	40	[1]
Exercise price range Expired	38.3
Exercise price range Outstanding at end of the year	0.01
Maximum [Member]
Equity (Details) - Schedule of Share Option Awards Outstanding and the Related Weighted Average Exercise Price [Line Items]
Exercise price range Outstanding at beginning of the year	247.1	[1]
Exercise price range Exercisable at end of the year	247.1	[1]
Exercise price range Granted	10.7	[1]
Exercise price range Forfeited	62.2	[1]
Exercise price range Expired	48.6	[1]
Exercise price range Outstanding at end of the year	$ 247.1	[1]
[1]Per 1 Ordinary Share of with no par value. Exercise price is quoted in denominated currency (see also Note 2B).[2]Average share price for options exercised in 2024 – $ 5.79 .

Schedule of Stock-Based Awards

Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding	Jun. 30, 2024 $ / shares shares
$10.7 - $0.01 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	39,083
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 10 months 24 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	36,083
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 2 months 12 days
$61.4 - $40.0 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	55,375
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 4 months 24 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	37,683
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 3 months 18 days
$76.7 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 76.7
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	19,425
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	1 year
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	14,569
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	1 year
USD 100 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 100
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	6,200
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	4 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	6,200
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years
$123.5; $185.3; $247.1 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	30,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 8 months 12 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	20,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	7 years 8 months 12 days
$0.01 - $247.1 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	150,083
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 9 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	114,535
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 8 months 12 days
Maximum [Member] | $10.7 - $0.01 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 10.7
Maximum [Member] | $61.4 - $40.0 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	61.4
Maximum [Member] | $123.5; $185.3; $247.1 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	247.1
Maximum [Member] | $0.01 - $247.1 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	247.1
Minimum [Member] | $10.7 - $0.01 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	0.01
Minimum [Member] | $61.4 - $40.0 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	40
Minimum [Member] | $123.5; $185.3; $247.1 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	123.5
Minimum [Member] | $0.01 - $247.1 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	0.01
Median [Member] | $123.5; $185.3; $247.1 [Member]
Schedule of Stock-Based Awards Outstanding (Details) - Schedule of Stock-Based Awards Outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 185.3

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of Share-Based Compensation Expense - Share-based compensation expense [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expenses	$ 915	$ 1,409
Cost of revenue [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expenses	8	68
Research and development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expenses	292	379
Sales and marketing [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expenses	124	209
General and administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expenses	$ 491	$ 753

Equity (Details) - Schedule o_4

Equity (Details) - Schedule of Fair Value of Option Grants was Estimated Using the Black-Scholes Pricing Model	6 Months Ended
	Jun. 30, 2024 $ / shares	Jun. 30, 2023 ₪ / shares
Equity (Details) - Schedule of Fair Value of Option Grants was Estimated Using the Black-Scholes Pricing Model [Line Items]
Risk-free interest rate		4.75%
Expected option term (in years)		10 years
Expected price volatility		76%
Fair value of an ordinary share (in New Shekels per share and Dollars per share) | ₪ / shares		₪ 32.6
Dividend yield	0%	0%
Minimum [Member]
Equity (Details) - Schedule of Fair Value of Option Grants was Estimated Using the Black-Scholes Pricing Model [Line Items]
Risk-free interest rate	3.92%
Expected option term (in years)	3 years
Expected price volatility	96%
Fair value of an ordinary share (in New Shekels per share and Dollars per share)	$ 2.17
Maximum [Member]
Equity (Details) - Schedule of Fair Value of Option Grants was Estimated Using the Black-Scholes Pricing Model [Line Items]
Risk-free interest rate	4.40%
Expected option term (in years)	5 years
Expected price volatility	103%
Fair value of an ordinary share (in New Shekels per share and Dollars per share)	$ 6.1

Certain Transactions (Details)

Certain Transactions (Details)	6 Months Ended
	Jun. 30, 2024
Certain Transactions [Abstract]
Percentage of royalties	10%

Supplementry Financial Statem_3

Supplementry Financial Statement Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Supplementry Financial Statement Information (Details) [Line Items]
Percentage from europe	100%
Revenue recognized		$ 175
Deferred revenue	$ 387		$ 387
Vested restricted shares (in Shares)	55,202
Share option and warrants exercisable (in Shares)	1,500,317
Write Off [Member]
Supplementry Financial Statement Information (Details) [Line Items]
Other operating expenses	$ 229
Treasury Stock Method, and Share Options [Member]
Supplementry Financial Statement Information (Details) [Line Items]
Shares exercisable (in Shares)	11,539

Supplementry Financial Statem_4

Supplementry Financial Statement Information (Details) - Schedule of Cost of Expenses (Cost of Revenues, Research and Development, Net, Selling and Marketing, General and Administrative) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Schedule of Cost of Expenses [Line Items]
General and Administrative, Net		$ 2,313	$ 2,409
Research and Development, Net		1,808	1,711
Cost of Revenues, Net		408	1,193
Cost of Revenues [Member]
Schedule of Cost of Expenses [Line Items]
Salary and related expenses			392
Consultants and subcontractors			112
Royalties			79
Cost of Revenues, Gross			583
Operating costs not attributed to projects (mainly salary and related expenses)	[1]	408	610
Research and Development, Net [Member]
Schedule of Cost of Expenses [Line Items]
Salary and related expenses		1,363	1,332
Consultants and subcontractors		210	188
Expenditure on materials		39	59
Depreciation and other		19	53
Office maintenance		177	173
Research and Development, Gross		1,808	1,805
Less - Government Grants			(94)
Selling and Marketing [Member]
Schedule of Cost of Expenses [Line Items]
Salary and related expenses		439	548
Office maintenance		18	18
Project Promotion		21	32
Consultants		51	59
Other		87	30
Selling and Marketing, Net		616	687
General and Administrative [Member]
Schedule of Cost of Expenses [Line Items]
Salary and related expenses		934	1,322
Depreciation and other		54	96
Office maintenance		91	88
Consultants and insurance		945	903
Allowance for credit losses		$ 289
[1]Cost and expenses relating to periods in which the plant did not operate in full capacity.

Supplementry Financial Statem_5

Supplementry Financial Statement Information (Details) - Schedule of Financial Income - USD ($) $ in Thousands		6 Months Ended
	May 23, 2024	Jun. 30, 2024	Jun. 30, 2023
Schedule of Financial Income [Abstarct]
Interest income		$ 76	$ 90
Fair value adjustments of warrants	$ (1,419)	4,114
Warrants issuance costs		(473)
Exchange rate differences, Net		172	56
Bank fees		(10)	(7)
Other adjustment of royalty obligation			20
Total		$ 3,879	$ 159

Supplementry Financial Statem_6

Supplementry Financial Statement Information (Details) - Schedule of Basic and Diluted Loss Per Share - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Schedule of Basic and Diluted Loss Per Share [Abstract]
Net loss for the year, as reported, attributable to shareholders (in Dollars)		$ (1,581)	$ (5,328)
Denominator (Ordinary Shares in thousands)
Weighted average number of shares outstanding during the year	[1]	2,941,377	1,749,876
Weighted average number of potential shares under prefunded warrants with token exercise price (“penny” warrants)		568,951	15,266
Denominator for basic loss per share - weighted number of Ordinary Shares		3,510,328	1,765,142
Basic loss per Ordinary Share (in dollars) (in Dollars per share)		$ (0.45)	$ (3.02)
[1]Including the equivalent of the weighted average number of fully vested restricted shares granted during the period of six month ended June 30, 2024 (see Note 5B) of 55,202 shares, that were formally issued subsequent to June 30, 2024).

Supplementry Financial Statem_7

Supplementry Financial Statement Information (Details) - Schedule of Basic and Diluted Loss Per Share (Parentheticals) - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Basic and Diluted Loss Per Share [Abstract]
Denominator for diluted loss per share - weighted number of Ordinary Shares	3,510,328	1,765,142
Dilutive loss per Ordinary Share (in dollars) (in Dollars per share)	$ (0.45)	$ (3.02)

Subsequent Events (Details)

Subsequent Events (Details) € in Millions				6 Months Ended
	Mar. 31, 2025	Aug. 04, 2024 $ / shares shares	Jul. 08, 2024 EUR (€)	Jun. 30, 2024 $ / shares shares
Subsequent Events [Line Items]
Extended period	1 year
Price per share | $ / shares				$ 2.5
Investor Pre-funded Warrants [Member]
Subsequent Events [Line Items]
Additional ordinary shares | shares				1,000,000
Investor Agreement Restriction [Member]
Subsequent Events [Line Items]
Ownership percentage				24.99%
Subsequent Event [Member]
Subsequent Events [Line Items]
Availability of second tranche | €			€ 3.5
Annual fixed interest rate			5%
Ordinary Shares [Member] | Pre-Funded Warrant [Member]
Subsequent Events [Line Items]
Purchase of ordinary share | shares				1,000,000
Price per ordinary share | $ / shares				$ 2.5
Private Placement [Member] | Ordinary Shares [Member] | Subsequent Event [Member]
Subsequent Events [Line Items]
Ordinary shares | shares		1,000,000
Price per share | $ / shares		$ 1.05